Apollomics (APLMW) News Today $0.02 +0.00 (+3.18%) As of 08/5/2025 03:43 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock APLMW Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business ProgressApril 3, 2025 | globenewswire.comApollomics and LaunXP Announce Development and Commercialization Agreement for VebreltinibMarch 31, 2025 | globenewswire.comApollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid LeukemiaDecember 20, 2024 | globenewswire.comApollomics Regains Compliance with Nasdaq's Minimum Bid Price RequirementDecember 10, 2024 | globenewswire.comApollomics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comApollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical ProgressAugust 14, 2024 | globenewswire.comApollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA TrialAugust 13, 2024 | globenewswire.comApollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price RequirementJuly 16, 2024 | globenewswire.comApollomics Announces Updated Strategic Focus and Leadership Team ChangesJuly 3, 2024 | globenewswire.comApollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion GeneApril 25, 2024 | globenewswire.comApollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingApril 10, 2024 | globenewswire.comApollomics Highlights Clinical Progress and Reports Full Year 2023 Financial ResultsMarch 28, 2024 | globenewswire.comApollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial OfficerMarch 4, 2024 | globenewswire.com Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLMW and its competitors with MarketBeat's FREE daily newsletter. Email Address APLMW Media Mentions By Week APLMW Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLMW News Sentiment▼0.000.46▲Average Medical News Sentiment APLMW News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLMW Articles This Week▼00▲APLMW Articles Average Week Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLMW and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SXTPW News DRTSW News BCTXW News ENGNW News FBIOP News GOVXW News JSPRW News LEXXW News NTRBW News RVPHW News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APLMW) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
